Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04004325 · ClinicalTrials.gov registry record · Phase 1
A Study of FT 4101 in Overweight/Obese Participants With Non-alcoholic Steatohepatitis
A Phase 1 study, sponsored by Forma Therapeutics.
- Terminated
- Registry status
- Phase 1
- Development phase
- 14
- Enrollment target
NCT04004325 is a Phase 1 study that was terminated before completion, run by Forma Therapeutics. The registered enrollment target is 14 participants.
The verdict
NCT04004325, a Phase 1 study, was terminated before completion, sponsored by Forma Therapeutics.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 14 participants
- Enrollment target
Study Summary
This Phase 1/2 study will evaluate safety, efficacy, PK, and PD of FT-4101 as a single agent in overweight/obese subjects with NASH. The study may be conducted in up to 2 dosing cohorts.
Interventions
- DRUG FT-4101
- DRUG FT-4101 placebo
- OTHER Deuterated Water
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2019-05-17 |
| Est. Completion | 2020-01-20 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04004325
The ClinicalTrials.gov registry entry for NCT04004325 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Forma Therapeutics, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which FT-4101 is the first listed.
NCT04004325 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04004325 about?
NCT04004325 is a clinical study titled "A Study of FT 4101 in Overweight/Obese Participants With Non-alcoholic Steatohepatitis". This Phase 1/2 study will evaluate safety, efficacy, PK, and PD of FT-4101 as a single agent in overweight/obese subjects with NASH. The study may be conducted in up to 2 dosing cohorts.
What is the current status of trial NCT04004325?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 14 participants. The study started on 2019-05-17. Estimated completion is 2020-01-20.
What interventions are being tested in trial NCT04004325?
The interventions under investigation include: FT-4101 (DRUG), FT-4101 placebo (DRUG), Deuterated Water (OTHER).
Who is sponsoring clinical trial NCT04004325?
This trial is sponsored by Forma Therapeutics, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.